These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11360239)

  • 21. Novel polyvalent live vaccine against varicella-zoster and mumps virus infections.
    Matsuura M; Somboonthum P; Murakami K; Ota M; Shoji M; Kawabata K; Mizuguchi H; Gomi Y; Yamanishi K; Mori Y
    Microbiol Immunol; 2013 Oct; 57(10):704-14. PubMed ID: 23905963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superiority of varicella skin test antigen over purified varicella-zoster virus glycoproteins in monitoring booster response to Oka varicella vaccine.
    Sato H; Yamamura Ji; Kageyama S; Kurokawa M; Shiraki K
    Vaccine; 2003 Dec; 22(1):15-20. PubMed ID: 14604566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a current varicella vaccine as a live polyvalent vaccine vector.
    Murakami K; Mori Y
    Vaccine; 2016 Jan; 34(2):296-298. PubMed ID: 25444800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis.
    Kimura H; Wang Y; Pesnicak L; Cohen JI; Hooks JJ; Straus SE; Williams RK
    J Infect Dis; 1998 Aug; 178(2):310-7. PubMed ID: 9697709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
    Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K; Sugiura W; Watanabe K; Fukushima Y; Haga S; Katsura Y; Tasaka H; Komuro K; Yamada T; Asano T; Yamazaki A; Yamazaki S
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10693-7. PubMed ID: 7479867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
    Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
    Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.
    Hovav AH; Santosuosso M; Bivas-Benita M; Plair A; Cheng A; Elnekave M; Righi E; Chen T; Kashiwagi S; Panas MW; Xiang SH; Furmanov K; Letvin NL; Poznansky MC
    J Virol; 2009 Nov; 83(21):10941-50. PubMed ID: 19692474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Whole-Genome Sequence of an Oka Varicella Vaccine from China with Other Oka Vaccine Strains Reveals Sites Putatively Critical for Vaccine Efficacy.
    Wu Q; Rivailler P; Xu S; Xu W
    J Virol; 2019 May; 93(9):. PubMed ID: 30728261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation.
    Jacquet A; Haumont M; Massaer M; Garcia L; Mazzu P; Daminet V; Grégoire D; Jacobs P; Bollen A
    Vaccine; 2002 Feb; 20(11-12):1593-602. PubMed ID: 11858867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity.
    Kawahara M; Hashimoto A; Toida I; Honda M
    Clin Immunol; 2002 Dec; 105(3):326-31. PubMed ID: 12498814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older.
    Berger R; Trannoy E; Holländer G; Bailleux F; Rudin C; Creusvaux H
    J Infect Dis; 1998 Nov; 178 Suppl 1():S99-103. PubMed ID: 9852985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization.
    Haumont M; Jurdan M; Kangro H; Jacquet A; Massaer M; Deleersnyder V; Garcia L; Bosseloir A; Bruck C; Bollen A; Jacobs P
    J Med Virol; 1997 Sep; 53(1):63-8. PubMed ID: 9298734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete DNA sequences of two oka strain varicella-zoster virus genomes.
    Tillieux SL; Halsey WS; Thomas ES; Voycik JJ; Sathe GM; Vassilev V
    J Virol; 2008 Nov; 82(22):11023-44. PubMed ID: 18787000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus.
    Cohrs RJ; Gilden DH; Gomi Y; Yamanishi K; Cohen JI
    J Virol; 2006 Mar; 80(5):2076-82. PubMed ID: 16474115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.